The Eye See You Program

Retinal diseases including Age-related Macular Degeneration and Diabetic Retinopathy cause irreversible vision loss in about 2 million Canadians. The goal of IFA in relation to vision and healthy ageing is to help ensure safe and appropriate treatments that are accessible to all Canadians. There is a growing trend worldwide to explore the use of biosimilars rather than biologics in various therapeutic areas.

Sound evidence-based policy must underpin governmental decisions in funding new treatments but also and equally important is the impact on patient treatment and the overall functional outcome. While biosimilars in ophthalmology have “not yet arrived” in Canada now is the time to bring together key patient advocates across various vantage points to gain a deeper understanding of policy development and the patient voice.

The Eye See You Biosimilars in Ophthalmology Program is committed to raising awareness about emerging biosimilars in ophthalmology and connecting Canadians to experts and thought leaders in vision health.


Vision Health Panel

The Vision Health Panel with leading experts in vision health and patient advocacy in Canada highlighted the importance of patient and caregiver education, in an era of emerging biosimilar policies.

Read the Vision Health Panel Executive Summary.

Panelists included: 

Dr. Dawn Richards
Vice President of the Canadian Arthritis Patient Alliance

Mr. Doug Earle
President and CEO of Fighting Blindness Canada (FBC)

Ms. Louise Gillis
President of the Canadian Council of the Blind (CCB)

 


An Educational Framework is the Missing Element in Canada’s Biosimilars Discourse: A Brief Report

While biosimilars are a relatively recent phenomenon in Canada, international experiences have demonstrated lessons about safety, efficacy, and implementation policies. In both peer-reviewed and gray literature a resounding lesson of critical importance is the need for a sound educational framework for health care professionals and patients on the appropriate uses of biosimilars.

This report based on an environmental scan explores the critical elements of educational frameworks in other therapeutic areas which have contributed to effective consultations between clinicians and their patients for the safe and appropriate use of biosimilars.

Read the Brief Report: An Educational Framework is the Missing Element in Canada’s Biosimilars Discourse.

 


What you can do

Learn more about biosimilars in ophthalmology, and the implications to your vision health, by registering for upcoming ESY initiatives:

  • Engage with us on Facebook and Twitter with #EyeSeeYouCare
  • Sign up for the ESY quarterly newsletter